Visit the ACCC COVID-19 Resource Center & Discussion Group for Insights on Providing Optimal Patient Care During the Pandemic.

Industry News Archive

  • Enhertu Receives Permanent J-Code

    Effective July 1, 2020, ENHERTU® (fam-trastuzumab deruxtecan-nxki) has a permanent j-code: J9358. ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2–based regimens in the metastatic setting.

    For full prescribing information, click here

    Posted 7/7/20



  • Update: COVID-19 Emergency Food Assistance Grant Amount Change

    Due to increasing demand for the program’s financial assistance, the individual grant award amount has been changed to $300 effective immediately. This adjustment will allow thousands of additional patients to receive meaningful financial support for nutritional needs while maximizing the reach of available funding as the number of people impacting by COVID 19 continues to accelerate.

    To date, the COVID-19 Emergency Food Assistance Program has helped more than 13,000 patients, including 1,000 emergency food deliveries made and over 12,000 financial assistance grants being provided to patients in all 50 states.  

    This innovative program is a collaboration between Team Rubicon (TR) and Patient Advocate Foundation (PAF) and provides emergency food delivery and financial assistance to people living with cancer, multiple sclerosis, and rheumatoid arthritis.

    Who is Eligible?

    Patients with cancer, multiple sclerosis or rheumatoid arthritis who have trouble accessing or affording food or other nutritional needs due to COVID-19, with eligibility established at the point of application in most cases.

    For more information, including application instructions, click here.  

    Posted 7/2/2020



  • FDA Approves Pembrolizumab for First-line Treatment of Metastatic MSI-H or dMMR CRC

    On June 29, 2020, the U.S. Food and Drug Administration approved pembrolizumab (Keytruda, Merck & Co.) for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.

    Read FDA announcement.

    Posted 6/30/2020



  • Live Discussion: CD38-Directed Antibody for the Treatment of RRMM

    CD38-Directed Antibody for the Treatment of Appropriate Relapsed Refractory Multiple Myeloma Patients
     
    Thursday, June 25
    5:00 PM PT

    Participants of this live discussion will be able to:

    • Learn about the indication, mechanism of action, and important safety information for Sarclisa (isatuximab-irfc)

    • Gain in-depth knowledge on clinical data in adult patients with relapsed refractory multiple myeloma

    • Understand the dosage and administration of Sarclisa.

    • Learn about support available for eligible patients treated with Sarclisa. 

    For registration information or to learn more, click here

    Posted 6/25/2020



  • Astellas and Seattle Genetics Issue Product-Specific J-code for PADCEV

    Astellas and Seattle Genetics are pleased to announce the assignment of a product-specific, permanent J-code for PADCEV. CMS released the July 2020 Quarterly Healthcare Common Procedural Coding System File, which includes the designation of J9177 for PADCEV with the effective date of July 1, 2020. 

    Read corporate announcement.

    Posted 6/25/20



  • FDA Approves Pembrolizumab for Recurrent or Metastatic cSCC

    On June 24, 2020, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck & Co., Inc.) for patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.

    Read the FDA announcement.

    Posted 6/24/2020



  • ELITEK Pivotal Trial Overview

    ELITEK (Sanofi-Genzyme) is indicated for the initial management of plasma uric acid levels in patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. ELITEK is indicated only for a single course of treatment.

    Read pivotal trial overview.

    Posted 6/22/2020



  • Taiho Oncology Patient Support Program

    Taiho Oncology Patient Support offers personalized services to give patients, caregivers, and healthcare professionals the help they need in getting started with Taiho Oncology Products. This includes insurance verification, help with medication costs, and treatment plan support.

    Learn more

    Posted 6/22/2020



  • Lonsurf Efficacy Flashcard

    Lonsurf®  (FTD/TPI, Taiho Oncology) is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.


    Read efficacy and safety information

    Posted 6/22/2020



  • Sanofi Introduces the Libtayo Surround Online Portal

    Healthcare providers can now help patients enroll in LIBTAYO Surround online portal.

    Click here for more information.

    Posted 6/22/2020




1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
laoncologysociety.org
Email Us